Our newest whitepaper, The Now & The Next in Pharma Marketing, explores practical solutions for the challenges that pharmaceutical organizations continue to face in light of the ongoing COVID-19 pandemic. Less a follow-up to our original COVID-19 whitepaper, and more a detailed, deeper dive, this report leverages new research insights, practical solutions and proven tactics to implement now and help you evolve your commercial strategy.

Even as vaccines are being administered and the “end” of COVID-19 appears to be in sight, much work remains as pharma marketers continue to respond to a constant state of evolution and uncertainty. The Now & The Next in Pharma Marketing reports on key relationships — pharma-to-professional, professional-to-patient and pharma-to-patient — with actionable recommendations, including how to:

* Rethink your sales force strategy
* Embrace opportunities at the point of care
* Optimize the rise of telemedicine
* Decide where to double down on digital


Thought Leaders Weigh In on The Future of Privacy First Marketing

The shift away from (browser-based) cookies by Apple, Firefox, and Google has ushered in a new era of targeting and audience metrics for brands, marketers, and agencies. This shift will have an acute impact on the approach pharma companies will have to take to successfully promote their products online.

The DHC Group and its members will be affected by these privacy-first changes – so we turned to our membership to gain a better understanding of some of the challenges and opportunities facing pharma brand marketers. The DHC Group interviewed more than 20 leading digital marketing experts from ad tech, data firms, agencies, publishers, and pharmaceutical organizations and asked them how they plan to adapt to the “privacy-first” era – and what’s ahead for audience targeting, tracking, and metrics.


We work as a team with market leading brands and organizations around the world and give our clients the highest quality research, insights, and advice possible.

Learn More